Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection

Journal of General Virology

Volumn 93, Issue 6, 2012, Pages 1305-1315

  Shlapobersky, Mark ^a   Marshak, Joshua O ^b   Dong, Lichun ^b   Huang, Meei li ^b   Wei, Qun ^a   Chu, Alice ^a   Rolland, Alain ^a   Sullivan, Sean ^a   Koelle, David M ^b,c,d  

^a VICAL INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PLASMID DNA; UNCLASSIFIED DRUG; VAXFECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION; SURVIVAL; VAGINA; VIRUS GENOME; VIRUS LATENCY; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; PHOSPHATIDYLETHANOLAMINES; PLASMIDS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

HERPES; HUMAN HERPESVIRUS 2; MURINAE; MUS;

EID: 84861161195     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.040055-0     Document Type: Article

References (64)

1. Aumakhan, B., Hardick, A., Quinn, T. C., Laeyendecker, O., Gange, S. J., Beyrer, C., Cox, C., Anastos, K., Cohen, M. & other authors (2010). Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. Virol J 7, 328.
2. Balachandran, N., Bacchetti, S. & Rawls, W. E. (1982). Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 37, 1132-1137.
3. Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., Gorfinkel, I., Morrow, R. L., Ewell, M. G. & other authors (2012). Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366, 34-43.
4. + Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol 77, 9463-9473.
5. Bernstein, D. I., Aoki, F. Y., Tyring, S. K., Stanberry, L. R., St-Pierre, C., Shafran, S. D., Leroux-Roels, G., Van Herck, K., Bollaerts, A., Dubin, G. & Glaxo Smith Kline Herpes Vaccine Study Group (2005). Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 40, 1271-1281.
6. Bourne, N., Milligan, G. N., Schleiss, M. R., Bernstein, D. I. & Stanberry, L. R. (1996). DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 14, 1230-1234.
7. Bourne, N., Pyles, R. B., Bernstein, D. I. & Stanberry, L. R. (2002). Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol 83, 2797-2801.
8. Bourne, N., Milligan, G. N., Stanberry, L. R., Stegall, R. & Pyles, R. B. (2005). Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192, 2117-2123.
9. Cattamanchi, A., Posavad, C. M., Wald, A., Baine, Y., Moses, J., Higgins, T. J., Ginsberg, R., Ciccarelli, R., Corey, L. & Koelle, D. M. (2008). Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 15, 1638-1643.
10. Chen, C. Y., Ballard, R. C., Beck-Sague, C. M., Dangor, Y., Radebe, F., Schmid, S., Weiss, J. B., Tshabalala, V., Fehler, G. & other authors (2000). Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 27, 21-29.
11. + cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 180, 426-437.
12. Coen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, C. L., Schaffer, P. A., Tyler, K. L. & Knipe, D. M. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 86, 4736-4740.
13. Cohen, J. (2010). Immunology. Painful failure of promising genital herpes vaccine. Science 330, 304.
14. Corey, L., Langenberg, A. G., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, J. M., Jr, Handsfield, H. H., Warren, T., Marr, L. & other authors (1999). Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282, 331-340.
15. Corey, L., Wald, A., Celum, C. L. & Quinn, T. C. (2004). The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 35, 435-445.
16. Dolan, A., Jamieson, F. E., Cunningham, C., Barnett, B. C. & McGeoch, D. J. (1998). The genome sequence of herpes simplex virus type 2. J Virol 72, 2010-2021.
17. Donnelly, J. J., Ulmer, J. B. & Liu, M. A. (1997). DNA vaccines. Life Sci 60, 163-172.
18. Fló, J. (2003). Co-immunization with plasmids coding the full length and a soluble form of glycoprotein D of HSV-2 induces protective cellular and humoral immune response in mice. Vaccine 21, 1239-1245.
19. Hartikka, J., Sawdey, M., Cornefert-Jensen, F., Margalith, M., Barnhart, K., Nolasco, M., Vahlsing, H. L., Meek, J., Marquet, M. & other authors (1996). An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7, 1205-1217.
20. Hartikka, J., Bozoukova, V., Ferrari, M., Sukhu, L., Enas, J., Sawdey, M., Wloch, M. K., Tonsky, K., Norman, J. & other authors (2001). Vaxfectin enhances the humoral immune response to plasmid DNAencoded antigens. Vaccine 19, 1911-1923.
21. Hermanson, G., Whitlow, V., Parker, S., Tonsky, K., Rusalov, D., Ferrari, M., Lalor, P., Komai, M., Mere, R. & other authors (2004). A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A 101, 13601-13606.
22. Higgins, T. J., Herold, K. M., Arnold, R. L., McElhiney, S. P., Shroff, K. E. & Pachuk, C. J. (2000). Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 182, 1311-1320.
23. + T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80, 5509-5515.
24. Iijima, N., Linehan, M. M., Zamora, M., Butkus, D., Dunn, R., Kehry, M. R., Laufer, T. M. & Iwasaki, A. (2008). Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 205, 3041-3052.
25. Jimenez, G. S., Planchon, R., Wei, Q., Rusalov, D., Geall, A., Enas, J., Lalor, P., Leamy, V., Vahle, R. & other authors (2007). Vaxfectinformulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3, 157-164.
26. Jing, L., McCaughey, S. M., Davies, D. H., Chong, T. M., Felgner, P. L., De Rosa, S. C., Wilson, C. B. & Koelle, D. M. (2009). ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 347, 36-45.
27. Kask, A. S., Chen, X., Marshak, J. O., Dong, L., Saracino, M., Chen, D., Jarrahian, C., Kendall, M. A. & Koelle, D. M. (2010). DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 28, 7483-7491.
28. Kemble, G. & Spaete, R. (2007). Herpes simplex vaccines. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, chapter 69. Edited by A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley & K. Yamanishi. Cambridge: Cambridge University Press.
29. Kim, M., Taylor, J., Sidney, J., Mikloska, Z., Bodsworth, N., Lagios, K., Dunckley, H., Byth-Wilson, K., Denis, M. & other authors (2008). Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 181, 6604-6615.
30. Klein, R. J. (1980). Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice. J Gen Virol 49, 401-405.
31. Koelle, D. M. & Corey, L. (2008). Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 59, 381-395.
32. Koelle, D. M., Benedetti, J., Langenberg, A. & Corey, L. (1992). Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 116, 433-437.
33. Koelle, D. M., Liu, Z., McClurkan, C. L., Cevallos, R. C., Vieira, J., Hosken, N. A., Meseda, C. A., Snow, D. C., Wald, A. & Corey, L. (2003). Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 100, 12899-12904.
34. Langenberg, A. G., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L. & Corey, L. (1995). A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 122, 889-898.
35. Long, D., Madara, T. J., Ponce de Leon, M., Cohen, G. H., Montgomery, P. C. & Eisenberg, R. J. (1984). Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect Immun 43, 761-764.
36. Malin, S. A., Davis, B. M. & Molliver, D. C. (2007). Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat Protoc 2, 152-160.
37. + T lymphocytes. J Immunol 155, 259-265.
38. Margalith, M. & Vilalta, A. (2006). Sustained protective rabies neutralizing antibody titers after administration of cationic lipidformulated pDNA vaccine. Genet Vaccines Ther 4, 2.
39. McClements, W. L., Armstrong, M. E., Keys, R. D. & Liu, M. A. (1996). Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A 93, 11414-11420.
40. Muller, W. J., Dong, L., Vilalta, A., Byrd, B., Wilhelm, K. M., McClurkan, C. L., Margalith, M., Liu, C., Kaslow, D. & other authors (2009). Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 90, 1153-1163.
41. Nass, P. H., Elkins, K. L. & Weir, J. P. (2001). Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 19, 1538-1546.
42. Pan, C. H., Jimenez, G. S., Nair, N., Wei, Q., Adams, R. J., Polack, F. P., Rolland, A., Vilalta, A. & Griffin, D. E. (2008). Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 15, 1214-1221.
43. Parr, M. B., Kepple, L., McDermott, M. R., Drew, M. D., Bozzola, J. J. & Parr, E. L. (1994). A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70, 369-380.
44. Perez, G., Skurnick, J. H., Denny, T. N., Stephens, R., Kennedy, C. A., Regivick, N., Nahmias, A., Lee, F. K., Lo, S. C. & other authors (1998). Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis 3, 5-11.
45. Rajcáni, J., Mosko, T. & Rezuchová, I. (2005). Current developments in viral DNA vaccines: shall they solve the unsolved? Rev Med Virol 15, 303-325.
46. Reyes, L., Hartikka, J., Bozoukova, V., Sukhu, L., Nishioka, W., Singh, G., Ferrari, M., Enas, J., Wheeler, C. J. & other authors (2001). Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19, 3778-3786.
47. Sawtell, N. M. (1998). The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 72, 6888-6892.
48. Sawtell, N. M., Poon, D. K., Tansky, C. S. & Thompson, R. L. (1998). The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol 72, 5343-5350.
49. Sawtell, N. M., Thompson, R. L., Stanberry, L. R. & Bernstein, D. I. (2001). Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 184, 964-971.
50. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L. & other authors (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
51. Simmons, A. & Nash, A. A. (1985). Role of antibody in primary and recurrent herpes simplex virus infection. J Virol 53, 944-948.
52. Sin, J. I., Ayyavoo, V., Boyer, J., Kim, J., Ciccarelli, R. B. & Weiner, D. B. (1999). Protective immune correlates can segregate by vaccine type in a murine herpes model system. Int Immunol 11, 1763-1773.
53. + T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 74, 11173-11180.
54. + T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum Gene Ther 12, 1091-1102.
55. Smith, L. R., Wloch, M. K., Ye, M., Reyes, L. R., Boutsaboualoy, S., Dunne, C. E., Chaplin, J. A., Rusalov, D., Rolland, A. P. & other authors (2010). Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28, 2565-2572.
56. Stanberry, L. R., Spruance, S., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M. & other authors (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347, 1652-1661.
57. Sullivan, S. M., Doukas, J., Hartikka, J., Smith, L. & Rolland, A. (2010). Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 7, 1433-1446.
58. Ulmer, J. B., DeWitt, C. M., Chastain, M., Friedman, A., Donnelly, J. J., McClements, W. L., Caulfield, M. J., Bohannon, K. E., Volkin, D. B. & Evans, R. K. (1999). Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18, 18-28.
59. Vilalta, A., Shlapobersky, M., Wei, Q., Planchon, R., Rolland, A. & Sullivan, S. (2009). Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA. Vaccine 27, 7409-7417.
60. Wald, A. & Corey, L. (2003). How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 187, 1509-1512.
61. Wald, A., Zeh, J., Selke, S., Warren, T., Ashley, R. & Corey, L. (2002). Genital shedding of herpes simplex virus among men. J Infect Dis 186 (Suppl. 1), S34-S39.
62. Wald, A., Huang, M. L., Carrell, D., Selke, S. & Corey, L. (2003). Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188, 1345-1351.
63. Watson, R. J. (1983). DNA sequence of the herpes simplex virus type 2 glycoprotein D gene. Gene 26, 307-312.
64. Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. M. & Markowitz, L. E. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964-973.